Identification of new allosteric sites and modulators of AChE through computational and experimental tools

Carlos Roca, Carlos Requeña, Víctor Sebastián-Pérez, Sony Malhotra, Chris J. Radoux, Concepción Pérez, Ana Martı́nez, Juan A. Páez, Tom L. Blundell, Nuria E. CampilloJournal of Enzyme Inhibition and Medicinal Chemistry 2018 · DOI

TL;DR

This study identifies novel allosteric binding sites on acetylcholinesterase (AChE) using computational methods, leading to the discovery of new allosteric inhibitors. These findings are crucial for understanding and potentially modulating AChE's non-cholinergic functions, which are implicated in diseases like Alzheimer's.

What Problem Does This Paper Address?

Acetylcholinesterase (AChE) is primarily known for its role in breaking down acetylcholine, a key neurotransmitter. This function makes it a primary target for Alzheimer's disease (AD) treatments. However, AChE also engages in "non-classical" functions, such as regulating cell development and adhesion, and its dysregulation in these roles can contribute to AD pathogenesis (e.g., amyloidosis). Current drugs targeting AChE often focus on its catalytic site, which may not address these non-hydrolytic functions and could even exacerbate certain conditions. The challenge lies in identifying and targeting these alternative, allosteric sites on AChE to specifically modulate its non-cholinergic activities without necessarily interfering with its essential hydrolytic function.

Methods

The researchers employed a multi-pronged computational and experimental approach:

  • Pocket Search: The Fpocket software was used to identify potential binding cavities on the AChE protein structure. This algorithm analyzes geometric parameters to define "a-spheres" and cluster them into pockets.
  • Fragment Hotspot Analysis: The Fragment Hotspot maps software was utilized to pinpoint regions on the protein surface that are favorable for fragment binding. This method identifies key interactions (H-bonds, hydrophobic, aromatic) that can guide inhibitor design.
  • Virtual Screening: A library of compounds (MBC library) was screened against the identified allosteric sites using the Glide software with an Extra Precision (XP) mode. This process predicts how well potential drug molecules might bind to the target sites.
  • Molecular Dynamics (MD) Simulations: MD simulations were performed using AMBER14 to assess the stability of ligand-protein complexes, understand conformational changes, and elucidate the mechanism of inhibition. This technique simulates the movement of atoms and molecules over time.
  • In Vitro Cholinesterase Inhibition Assays: Standard biochemical assays were used to measure the ability of identified compounds to inhibit AChE activity.
  • Kinetic Studies: Lineweaver-Burk plots were used to determine the type of inhibition (e.g., competitive, non-competitive) exhibited by the identified compounds.

Datasets

  • Protein Data Bank (PDB): Fourteen human AChE (hAChE) structures in various states (apo and complexed with ligands) were downloaded from the PDB (PDB IDs: 1B41, 1F8U, 2X8B, 3LII, 4BDT, 4EY4, 4EY5, 4EY6, 4EY7, 4EY8, 4M0E, 4M0F, 4PQE, 5FPQ).
  • MBC Library: A proprietary in-house library of 1830 compounds was used for virtual screening.

Key Insights and Ideas

  • Discovery of Novel Allosteric Sites: Beyond the known peripheral anionic site (PAS), the study successfully identified two new putative allosteric sites (Site 2 and Site 3) on AChE using a combination of pocket detection and hotspot analysis.
  • Structure-Based Drug Design Strategy: The integration of computational tools like Fpocket and Fragment Hotspot maps provided a robust strategy for identifying druggable allosteric sites and their key interacting residues, paving the way for structure-based inhibitor design.
  • Allosteric Inhibition Mechanism: The identified compounds demonstrated non-competitive or mixed-non-competitive inhibition, strongly suggesting they bind to allosteric sites rather than the catalytic active site. This is a critical finding for developing selective modulators.
  • Dynamic Nature of Allosteric Sites: Molecular dynamics simulations revealed that the volume of allosteric sites can fluctuate upon ligand binding, hinting at dynamic allosteric mechanisms that could influence enzyme activity.
  • Potential for Modulating Non-Cholinergic Functions: The identified allosteric inhibitors, particularly SC251 for Site 2 and VP2.33/SC035 for Site 3, offer valuable pharmacological tools to investigate and potentially target AChE's less understood non-cholinergic roles.

Key Results

  • Identification of Sites 2 and 3: Two novel allosteric sites, designated Site 2 and Site 3, were identified and characterized. Site 2 showed interactions with residues like Gln413, Trp532, and His405, while Site 3 involved residues such as Glu81, Glu452, and Arg463.
  • Discovery of Active Allosteric Inhibitors:
    • Site 2: The pteridine derivative SC251 emerged as a potent allosteric inhibitor with an IC50 of 2.7 µM, exhibiting non-competitive-mixed inhibition.
  • Site 3: Compounds VP2.33 and SC035 showed inhibitory activity with IC50 values around 50 µM and demonstrated non-competitive inhibition. Furthermore, VP2.33 showed cooperative inhibition with a known competitive inhibitor, supporting its allosteric binding.
  • MD Simulation Insights: Molecular dynamics studies provided evidence for the stability of ligand binding and suggested that inhibitors like SC251 might restrict the opening of the "side door" of AChE, while VP2.33 might influence the "omega loop" and prevent side door opening, thereby affecting product clearance.

Limitations and Future Work

  • Site 4: The study identified a fourth potential cavity (Site 4) but did not pursue its investigation due to a lack of immediate functional attribution. The authors suggest that Site 4 remains an open avenue for future work in designing new allosteric modulators.
  • SC035 Cooperativity: While VP2.33 showed cooperative inhibition with a known competitive inhibitor, the results for SC035 were not conclusive in demonstrating this cooperative behavior, suggesting potential differences in their allosteric mechanisms.
  • Further Experimental Validation: Although experimental studies were conducted, further in-depth investigations are needed to fully elucidate the precise allosteric mechanisms of the identified compounds and their impact on AChE's diverse functions.
  • Broader Pharmacological Applications: The authors propose that these newly identified allosteric modulators could serve as valuable pharmacological tools for exploring the complex roles of AChE beyond its cholinergic functions, particularly in neurodegenerative diseases.

Summary updated

Abstract

Allosteric sites on proteins are targeted for designing more selective inhibitors of enzyme activity and to discover new functions. Acetylcholinesterase (AChE), which is most widely known for the hydrolysis of the neurotransmitter acetylcholine, has a peripheral allosteric subsite responsible for amyloidosis in Alzheimer's disease through interaction with amyloid β-peptide. However, AChE plays other non-hydrolytic functions. Here, we identify and characterise using computational tools two new allosteric sites in AChE, which have allowed us to identify allosteric inhibitors by virtual screening guided by structure-based and fragment hotspot strategies. The identified compounds were also screened for in vitro inhibition of AChE and three were observed to be active. Further experimental (kinetic) and computational (molecular dynamics) studies have been performed to verify the allosteric activity. These new compounds may be valuable pharmacological tools in the study of non-cholinergic functions of AChE.
BibTeX
@article{roca2018identification,
  author = {Carlos Roca and Carlos Requeña and Víctor Sebastián-Pérez and Sony Malhotra and Chris J. Radoux and Concepción Pérez and Ana Martı́nez and Juan A. Páez and Tom L. Blundell and Nuria E. Campillo},
  title = {{Identification of new allosteric sites and modulators of AChE through computational and experimental tools}},
  journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
  year = {2018},
  doi = {10.1080/14756366.2018.1476502},
}
Figure